Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Real-life effectiveness of first-line anticancer treatments in stage IIIB/IV NSCLC patients: Data from the Czech TULUNG Registry

K. Brat, M. Bratova, J. Skrickova, M. Barinova, K. Hurdalkova, M. Pesek, L. Havel, L. Koubkova, M. Hrnciarik, J. Krejci, O. Fischer, M. Zemanova, H. Coupkova, M. Svaton

. 2020 ; 11 (11) : 3346-3356. [pub] 20201005

Language English Country Singapore

Document type Journal Article, Research Support, Non-U.S. Gov't

Persistent link   https://www.medvik.cz/link/bmc21026471

Grant support
MH CZ-DRO FNBr 65269705 Ministerstvo Zdravotnictví Ceské Republiky - International

BACKGROUND: Data regarding real-life effectiveness of any treatment may improve clinical decision-making. The aim of this study was to evaluate real-life effectiveness of tyrosin-kinase inhibitors, bevacizumab and pemetrexed as first-line treatments in patients with advanced/metastatic non-small cell lung cancer (NSCLC). METHODS: We analyzed data of 2157 patients of the Czech TULUNG Registry of patients with advanced/metastatic NSCLC who received modern-era treatments between 2011 and 2018. Patients treated with gefitinib, erlotinib, afatinib, bevacizumab (+ maintenance), pemetrexed (+ maintenance) as first-line therapy were included in the study. A systematic literature search separately identified clinical trials suitable for calculation of comparator pooled OS and PFS for each regimen. For each subgroup, basic characteristics and survival data (Kaplan-Meier estimates) are shown. We propose the "index of real-life effectiveness" (IRE), a ratio of real-life OS/PFS and comparator pooled OS/PFS. Univariate and multivariate logistic regression identified factors were associated with longer OS (ie, IRE>1.1). RESULTS: Survival analysis showed median OS of 23 months for erlotinib, 29.3 months for afatinib, 19.6 months for gefitinib, 12.2 months for pemetrexed, 17.5 months for pemetrexed maintenance, 15.8 months for bevacizumab and 15.8 months for bevacizumab maintenance. Calculated IREs for OS for the regimens were: erlotinib 1.013, afatinib 1.184, gefitinib 0.736, pemetrexed 1.188, pemetrexed maintenance 1.294, bevacizumab 1.178, and bevacizumab maintenance 1.189. Multivariate regression analysis showed that these factors were associated with longer OS: lower PS for afatinib; lower PS, absence of adverse events and female sex for bevacizumab; and lower PS and female sex for pemetrexed. CONCLUSIONS: This study clearly demonstrated that real-life effectiveness of certain treatment regimens may strongly differ in various populations/health care systems, and comparison between TULUNG data and pooled survival data from trials showed higher real-life effectiveness for most of the studied first-line regimens. Lower ECOG PS, younger age, female sex and adverse events were associated with longer survival in most regimens. KEY POINTS: SIGNIFICANT FINDINGS OF THE STUDY: Comparison between TULUNG data and pooled survival data from trials showed higher real-life effectiveness for most of the studied first-line regimens; for most regimens, lower ECOG PS, younger age, female sex and adverse events were associated with longer survival. WHAT THIS STUDY ADDS: Real-life effectiveness of certain treatment regimens may strongly differ in various populations/health care systems.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc21026471
003      
CZ-PrNML
005      
20211026132902.0
007      
ta
008      
211013s2020 si f 000 0|eng||
009      
AR
024    7_
$a 10.1111/1759-7714.13679 $2 doi
035    __
$a (PubMed)33016001
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a si
100    1_
$a Brat, Kristian $u Department of Respiratory Diseases, University Hospital Brno, Brno, Czech Republic $u Faculty of Medicine, Masaryk University, Brno, Czech Republic
245    10
$a Real-life effectiveness of first-line anticancer treatments in stage IIIB/IV NSCLC patients: Data from the Czech TULUNG Registry / $c K. Brat, M. Bratova, J. Skrickova, M. Barinova, K. Hurdalkova, M. Pesek, L. Havel, L. Koubkova, M. Hrnciarik, J. Krejci, O. Fischer, M. Zemanova, H. Coupkova, M. Svaton
520    9_
$a BACKGROUND: Data regarding real-life effectiveness of any treatment may improve clinical decision-making. The aim of this study was to evaluate real-life effectiveness of tyrosin-kinase inhibitors, bevacizumab and pemetrexed as first-line treatments in patients with advanced/metastatic non-small cell lung cancer (NSCLC). METHODS: We analyzed data of 2157 patients of the Czech TULUNG Registry of patients with advanced/metastatic NSCLC who received modern-era treatments between 2011 and 2018. Patients treated with gefitinib, erlotinib, afatinib, bevacizumab (+ maintenance), pemetrexed (+ maintenance) as first-line therapy were included in the study. A systematic literature search separately identified clinical trials suitable for calculation of comparator pooled OS and PFS for each regimen. For each subgroup, basic characteristics and survival data (Kaplan-Meier estimates) are shown. We propose the "index of real-life effectiveness" (IRE), a ratio of real-life OS/PFS and comparator pooled OS/PFS. Univariate and multivariate logistic regression identified factors were associated with longer OS (ie, IRE>1.1). RESULTS: Survival analysis showed median OS of 23 months for erlotinib, 29.3 months for afatinib, 19.6 months for gefitinib, 12.2 months for pemetrexed, 17.5 months for pemetrexed maintenance, 15.8 months for bevacizumab and 15.8 months for bevacizumab maintenance. Calculated IREs for OS for the regimens were: erlotinib 1.013, afatinib 1.184, gefitinib 0.736, pemetrexed 1.188, pemetrexed maintenance 1.294, bevacizumab 1.178, and bevacizumab maintenance 1.189. Multivariate regression analysis showed that these factors were associated with longer OS: lower PS for afatinib; lower PS, absence of adverse events and female sex for bevacizumab; and lower PS and female sex for pemetrexed. CONCLUSIONS: This study clearly demonstrated that real-life effectiveness of certain treatment regimens may strongly differ in various populations/health care systems, and comparison between TULUNG data and pooled survival data from trials showed higher real-life effectiveness for most of the studied first-line regimens. Lower ECOG PS, younger age, female sex and adverse events were associated with longer survival in most regimens. KEY POINTS: SIGNIFICANT FINDINGS OF THE STUDY: Comparison between TULUNG data and pooled survival data from trials showed higher real-life effectiveness for most of the studied first-line regimens; for most regimens, lower ECOG PS, younger age, female sex and adverse events were associated with longer survival. WHAT THIS STUDY ADDS: Real-life effectiveness of certain treatment regimens may strongly differ in various populations/health care systems.
650    _2
$a protokoly protinádorové kombinované chemoterapie $x farmakologie $x terapeutické užití $7 D000971
650    _2
$a nemalobuněčný karcinom plic $x farmakoterapie $x mortalita $x patologie $7 D002289
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a nádory plic $x farmakoterapie $x mortalita $x patologie $7 D008175
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a staging nádorů $7 D009367
650    _2
$a registrace $7 D012042
650    _2
$a analýza přežití $7 D016019
651    _2
$a Česká republika $7 D018153
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Bratova, Monika $u Department of Respiratory Diseases, University Hospital Brno, Brno, Czech Republic $u Faculty of Medicine, Masaryk University, Brno, Czech Republic
700    1_
$a Skrickova, Jana $u Department of Respiratory Diseases, University Hospital Brno, Brno, Czech Republic $u Faculty of Medicine, Masaryk University, Brno, Czech Republic
700    1_
$a Barinova, Magda $u Institute of Biostatistics and Analyses, Ltd., Brno, Czech Republic
700    1_
$a Hurdalkova, Karolina $u Institute of Biostatistics and Analyses, Ltd., Brno, Czech Republic
700    1_
$a Pesek, Milos $u Department of Pneumology, University Hospital Pilsen, Pilsen, Czech Republic $u Faculty of Medicine, Charles University in Prague, Pilsen, Czech Republic
700    1_
$a Havel, Libor $u Department of Respiratory Medicine, Thomayer Hospital, Prague, Czech Republic
700    1_
$a Koubkova, Leona $u Department of Pneumology, University Hospital Motol, Prague, Czech Republic $u 2nd Faculty of Medicine, Charles University, Prague, Czech Republic
700    1_
$a Hrnciarik, Michal $u Department of Pneumology, University Hospital Hradec Kralove, Hradec Kralove, Czech Republic $u Faculty of Medicine, Charles University in Prague, Hradec Kralove, Czech Republic
700    1_
$a Krejci, Jana $u Department of Pneumology and Thoracic Surgery, Bulovka Hospital, Prague, Czech Republic
700    1_
$a Fischer, Ondrej $u Department of Respiratory Medicine, University Hospital Olomouc, Olomouc, Czech Republic $u Faculty of Medicine, Palacky University, Olomouc, Czech Republic
700    1_
$a Zemanova, Milada $u Department of Oncology, General Teaching Hospital, Prague, Czech Republic $u 1st Faculty of Medicine, Charles University, Prague, Czech Republic
700    1_
$a Coupkova, Helena $u Clinic of Comprehensive Cancer Care, Masaryk Memorial Cancer Institute, Brno, Czech Republic
700    1_
$a Svaton, Martin $u Department of Pneumology, University Hospital Pilsen, Pilsen, Czech Republic $u Faculty of Medicine, Charles University in Prague, Pilsen, Czech Republic
773    0_
$w MED00208286 $t Thoracic cancer $x 1759-7714 $g Roč. 11, č. 11 (2020), s. 3346-3356
856    41
$u https://pubmed.ncbi.nlm.nih.gov/33016001 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20211013 $b ABA008
991    __
$a 20211026132908 $b ABA008
999    __
$a ok $b bmc $g 1715251 $s 1146978
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2020 $b 11 $c 11 $d 3346-3356 $e 20201005 $i 1759-7714 $m Thoracic cancer $n Thorac Cancer $x MED00208286
GRA    __
$a MH CZ-DRO FNBr 65269705 $p Ministerstvo Zdravotnictví Ceské Republiky $2 International
LZP    __
$a Pubmed-20211013

Find record

Citation metrics

Archiving options